Source:http://linkedlifedata.com/resource/pubmed/id/11426555
Switch to
| Predicate | Object |
|---|---|
| rdf:type | |
| lifeskim:mentions | |
| pubmed:issue |
3-4
|
| pubmed:dateCreated |
2001-6-27
|
| pubmed:abstractText |
Progress in treatment of acute myeloid leukemia (AML) is slow and treatment intensification alone has limited effects, particularly in poor-risk cases. Poor-risk cases, that are identified mainly by prior history, leukemic cell mass and cytogenetic abnormalities, share multiple mechanisms of drug resistance that are responsible for treatment failure. Since Pgp-mediated resistance to anthracycline can be reduced with Idarubicin (IDA) and resistance to arabinosyl cytosine (AC) can be reduced with Fludarabine (FLUDA), we tested a combination of high dose AC (2000 mg/sqm, 5 doses), FLUDA (30 mg/sqm, 5 doses) and IDA (12 mg/sqm, 3 doses) for remission induction and consolidation in 45 consecutive cases of poor-risk AML. The complete remission (CR) rate was 71% after the first course and 82% overall, with a projected 2-year survival and relapse-free survival of 44% and 50% respectively. Non-hematologic toxicity was very mild, that is very important in elderly patients, but hemopoietic toxicity was substantial, with a time to hematologic recovery of 3 to 4 weeks and two cases of death in CR. Peripheral blood stem cells (PBSC) could be mobilized and collected successfully only in 11 cases. This three-drug combination is effective and has a limited non-hematologic toxicity, but FLUDA may increase the difficulty of obtaining PBSC early after remission induction.
|
| pubmed:language |
eng
|
| pubmed:journal | |
| pubmed:citationSubset |
IM
|
| pubmed:chemical | |
| pubmed:status |
MEDLINE
|
| pubmed:month |
Jan
|
| pubmed:issn |
1042-8194
|
| pubmed:author |
pubmed-author:BaccaraniMM,
pubmed-author:BertoneAA,
pubmed-author:BucalossiAA,
pubmed-author:De VivoAA,
pubmed-author:GobbiMM,
pubmed-author:LauriaFF,
pubmed-author:MarinLL,
pubmed-author:MazzaPP,
pubmed-author:MicheluttiAA,
pubmed-author:MichieliMM,
pubmed-author:PierreMM,
pubmed-author:PricoloGG,
pubmed-author:RaspadoriDD,
pubmed-author:RussoDD,
pubmed-author:ZaccariaAA,
pubmed-author:ZuffaEE
|
| pubmed:issnType |
Print
|
| pubmed:volume |
40
|
| pubmed:owner |
NLM
|
| pubmed:authorsComplete |
Y
|
| pubmed:pagination |
335-43
|
| pubmed:dateRevised |
2006-11-15
|
| pubmed:meshHeading |
pubmed-meshheading:11426555-Acute Disease,
pubmed-meshheading:11426555-Adolescent,
pubmed-meshheading:11426555-Adult,
pubmed-meshheading:11426555-Antineoplastic Combined Chemotherapy Protocols,
pubmed-meshheading:11426555-Cohort Studies,
pubmed-meshheading:11426555-Cytarabine,
pubmed-meshheading:11426555-Disease-Free Survival,
pubmed-meshheading:11426555-Female,
pubmed-meshheading:11426555-Humans,
pubmed-meshheading:11426555-Idarubicin,
pubmed-meshheading:11426555-Leukemia, Myeloid,
pubmed-meshheading:11426555-Male,
pubmed-meshheading:11426555-Middle Aged,
pubmed-meshheading:11426555-Pancytopenia,
pubmed-meshheading:11426555-Pilot Projects,
pubmed-meshheading:11426555-Remission Induction,
pubmed-meshheading:11426555-Salvage Therapy,
pubmed-meshheading:11426555-Survival Analysis,
pubmed-meshheading:11426555-Survival Rate,
pubmed-meshheading:11426555-Vidarabine
|
| pubmed:year |
2001
|
| pubmed:articleTitle |
Fludarabine, arabinosyl cytosine and idarubicin (FLAI) for remission induction in poor-risk acute myeloid leukemia.
|
| pubmed:affiliation |
Department of Bone Marrow Transplantation, University of Udine, Italy. Domenico@Russo@drmm.uniud.it
|
| pubmed:publicationType |
Journal Article,
Clinical Trial,
Research Support, Non-U.S. Gov't
|